Dr. Sun received his B.S. (1987) and M.S. (1990) from Xiamen University and earned his Ph.D. (1999) from Fudan University, P.R. China. In the same year, he joined the faculty of Tulane University Health Sciences Center as a research instructor in the Department of Medicine, Peptide Research Section, chaired by Dr. David H. Coy. Dr. Sun was promoted to research assistant professor in 2003 and research associate professor in 2007. In Dr. Coy's peptide research group, Dr. Sun established and is in charge of the biological branch of the laboratories. Dr. Sun's current research focuses on the development of peptide-based drugs and drug delivery systems in cancer therapeutics and their relevant mechanisms.
Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH. Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anti-Cancer Drugs, 18(3): 341-8, 2007.
Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Letters, 246(1-2): 157-66, 2007.
Moody TW, Sun LC, Mantey SA, Pradhan T, Coy DH, Jensen RT, et al. In vitro and in vivo anti-tumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther, 318(3): 1265-1272, 2006.
Sun LC, Fuselier JA, Coy DH, et al. Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Delivery, 11(4): 231-238, 2004.
Sun LC, Vasilevich NI, Coy DH, et al. Abilities of 3,4-diarylfuran-2-one analogues of combretastatin A-4 to inhibit proliferation of tumor cell lines and growth of the relevant tumors in nude mice. Anticancer Research, 24(1): 179-186, 2004.
Sun LC, Vasilevich NI, Coy DH, et al. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg & Med Chem Lett, 14(9): 2041-2046, 2004.
Fuselier JA, Sun LC, Woltering SN, Murphy WA, Vasilevich NI, Coy DH. An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg & Med Chem Lett, 13(5): 799-803, 2003.
Sun LC, Fuselier JA, Coy DH, et al. Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxicity to human neuroblastoma IMR32 cells expressing somatostatin receptors. Peptides, 23(9): 1557-1565, 2002.